Sanofi taps Kali for rights to clinical trispecific for immunology: Deals Report

Five days after Kali said it had dosed the first patient in a clinical study of trispecific T cell engager KT501 to treat rheumatoid arthritis, the biotech has granted Sanofi a license to the program in exchange for $180 million in up-front and near-term payments.

Sanofi (Euronext:SAN; NASDAQ:SNY) will gain an exclusive, worldwide license to KT501, which Kali Therapeutics Inc. believes has potential across numerous B cell-mediated immunological conditions. Their agreement also includes more than $1 billion in milestones, plus tiered royalties up to double digits...